KOD — Kodiak Sciences Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1468748 ·
Last close
$32.35
Market Cap
$2.03B
52W High
$47.84
52W Low
$10.94
ADV30
757,623
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -66,838,000 | -65,643,000 | 256,811,000 | 125,903,000 | 195,715,000 |
| Mar 2026 | 0 | — | -59,777,000 | -58,158,000 | 306,006,000 | 169,530,000 | 193,905,000 |
| Dec 2025 | 0 | — | -57,453,000 | -56,736,000 | 351,533,000 | 209,862,000 | 194,150,000 |
| Sep 2025 | 0 | — | -62,352,000 | -61,457,000 | 218,069,000 | 72,038,000 | 194,377,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-146,940,000
Investing CF
$-1,178,000
Financing CF
$178,797,000
CapEx
$-1,178,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.17
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,616,863,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-230,671,000
Pretax Income TTM
$-230,664,000
Interest Exp TTM
$0
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -234,388,000 | -229,967,000 | 351,533,000 | 194,150,000 | 157,383,000 | -136,008,000 |
| Dec 2024 | 0 | -186,849,000 | -176,207,000 | 335,578,000 | 185,290,000 | 150,288,000 | -117,319,000 |
| Dec 2023 | 0 | -277,321,000 | -260,491,000 | 479,372,000 | 213,591,000 | 265,781,000 | -154,183,000 |
| Dec 2022 | 0 | -341,379,000 | -333,823,000 | 666,628,000 | 230,461,000 | 436,167,000 | -206,459,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.75
Max Pain — expiry 2026-10-16
max pain strike: $41.00 · spot: $81.67 · call oi: 15,234 · put oi: 22Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VCEL | Vericel Corp | $2.03B | $39.71 | — |
| ALVO | Alvotech | $2.05B | $5.75 | — |
| RXRX | RECURSION PHARMACEUTICALS, INC. | $2.00B | $3.74 | — |
| ADMA | ADMA BIOLOGICS, INC. | $2.10B | $9.38 | — |
| MESO | MESOBLAST LTD | $1.96B | $15.12 | — |
News headlines (Yahoo Finance, 1h cache)
This Biotech Company Added Nearly $3B To Its Market Cap – Here’s Why KOD Stock Is Ripping Today
2026-09-28 14:14 · Yahoo
Kodiak Sciences stock soars on positive AMD trial data
2026-09-28 13:16 · Yahoo
Kodiak Sciences Stock Pops 70% After Eye-Disease Drugs Pass Key Trial
2026-09-28 11:58 · Yahoo
Kodiak Sciences Shares Rise After DAYBREAK Phase 3 Trial Results
2026-09-28 11:02 · Yahoo
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
2026-09-25 22:01 · Yahoo
Upcoming DAYBREAK Trial Results in Wet AMD Could Be A Game Changer For Kodiak Sciences (KOD)
2026-09-24 13:15 · Yahoo
Kodiak Sciences (KOD) Stock Looks Overvalued After Its 15x Run
2026-09-24 06:13 · Yahoo
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte
2026-09-23 12:37 · Yahoo
3 Small-Cap Biotechs With Binary Catalysts on the Calendar
2026-09-13 14:50 · Yahoo
Kodiak Sciences (KOD) Races Toward Three Make-Or-Break Trial Verdicts
2026-09-03 10:58 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.